Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Specialty pharma company Knight Therapeutics nets $70mm in bought deal

Executive Summary

Knight Therapeutics Inc. (specialty pharmaceuticals) netted $70mm in an up-sized bought deal financing consisting of 10mm (originally planned for 7.5mm; includes full exercise of 1.3mm over-allotment option) common shares at $7.40 ($Cdn10; 5% discount). The company will use the proceeds for future growth.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies